Exclusive Online Content
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation recently announced the creation of a subgroup of researchers to focus on cancer treatment. ….
Valneva & Pfizer Enter Equity Subscription Agreement & Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. recently announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15…..
Mitsubishi Gas Chemical & BD Have Signed LOI to Discuss Partnership Agreement to Explore New Ways to Advance Biologic Drug Delivery
Mitsubishi Gas Chemical Company, Inc. and BD recently announced they have entered into an agreement to investigate further development of OXYCAPT – an innovation from MGC that integrates….
Owen Mumford Appoints New Director of R&D
Owen Mumford, a global leader in the design, manufacture, and advancement of medical devices recently announced it has appointed….
Kindeva Drug Delivery Announces Collaboration With Synopsys
Kindeva Drug Delivery recently announced a collaboration with Synopsys, Inc. involving the implementation of Synopsys Simpleware automated software solutions to assist in creating….
medmix Drug Delivery (Haselmeier) Launches its First Fully Featured Autoinjector
medmix Drug Delivery introduces PiccoJect, a disposable two-step autoinjector designed for subcutaneous injection. The device is being developed in two variants (PiccoJect 100 and PiccoJect 225) for a standard….
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, a Type of Brain Cancer That Affects Predominantly Pediatric Patients
Nuvectis Pharma, Inc. recently announced positive data for NXP900 in a preclinical xenograft model of Group 4 Medulloblastoma presented on June 12, 2022, at SIOPE Brain Tumour Group in Hamburg, Germany, by scientists….
Pike Therapeutics Announces Positive Pharmacokinetic Animal Study Results & Unexpected Benefits for its Proprietary Weekly CBD Continuous Transdermal Delivery Technology
Pike Therapeutics Inc. has recently completed a preliminary pharmacokinetic rabbit study with its CBD formulations that yielded positive early results. This study demonstrated….
Exavir Therapeutics Announces Preclinical Data for Ultra-Long-Acting Dolutegravir Prodrug XVIR-120
Exavir Therapeutics recently announced the publication of preclinical data for XVIR-120, an investigational agent being developed as a long-acting injectable antiviral for HIV….
Replicate Bioscience & Curia Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA
Replicate Bioscience and Curia, formerly AMRI, recently announced they will collaborate on a robust development platform for Replicate’s srRNA therapeutics. The strategic collaboration unites….
EXCLUSIVE ONLINE CONTENT
Biolojic Design Announces Nektar Therapeutics Has Exercised its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021….
Cellares & Bristol Myers Squibb Announce $380-M Worldwide Capacity Reservation & Supply Agreement
Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will allocate multiple Cell Shuttles and its fully automated, high-throughput Cell Q systems across its IDMO Smart Factories in the US, EU, and Japan for Bristol Myers Squibb’s use ….
Neurolentech Signs Technology Access Partnership With Kaerus Bioscience
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes….
Palisade Bio Enters Strategic Collaboration With Strand Life Sciences to Advance Precision Medicine Approach
Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers….
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….